Comparison 2. Gluco+IFN versus Control+IFN (low and high quality trials at maximal follow‐up).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Loss of HBeAg	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [1.03, 1.92]
1.1 Low quality trials	6	189	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.17 [0.65, 2.10]
1.2 High quality trials	7	601	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.51 [1.05, 2.17]
2 HBeAg to anti‐HBe seroconversion	8	554	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.26 [0.87, 1.82]
2.1 Low quality trials	4	145	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.14 [0.59, 2.20]
2.2 High quality trials	4	409	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.32 [0.85, 2.06]
3 Loss of HBsAg	11	705	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [0.77, 2.59]
3.1 Low quality trials	5	180	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.45 [0.52, 4.08]
3.2 High quality trials	6	525	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.39 [0.65, 2.94]
4 Loss of HBV DNA	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.51 [1.12, 2.05]
4.1 Low quality trials	6	189	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.18 [0.66, 2.08]
4.2 High quality trials	7	601	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.67 [1.17, 2.40]
5 Normalisation of ALT or AST activities	9	583	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.12 [0.78, 1.62]
5.1 Low quality trials	4	121	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.12 [0.54, 2.31]
5.2 High quality trials	5	462	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.13 [0.74, 1.72]